Janone (ALTS) Competitors $4.43 -0.13 (-2.85%) Closing price 04:00 PM EasternExtended Trading$4.46 +0.04 (+0.79%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ALTS vs. DMAC, CDTX, OLMA, ACB, LFCR, ATAI, KRRO, PRME, ACIU, and BTMDShould you be buying Janone stock or one of its competitors? The main competitors of Janone include DiaMedica Therapeutics (DMAC), Cidara Therapeutics (CDTX), Olema Pharmaceuticals (OLMA), Aurora Cannabis (ACB), Lifecore Biomedical (LFCR), Atai Life Sciences (ATAI), Korro Bio (KRRO), Prime Medicine (PRME), AC Immune (ACIU), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. Janone vs. DiaMedica Therapeutics Cidara Therapeutics Olema Pharmaceuticals Aurora Cannabis Lifecore Biomedical Atai Life Sciences Korro Bio Prime Medicine AC Immune biote DiaMedica Therapeutics (NASDAQ:DMAC) and Janone (NASDAQ:ALTS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment. Which has more risk and volatility, DMAC or ALTS? DiaMedica Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Janone has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Do institutionals & insiders hold more shares of DMAC or ALTS? 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of Janone shares are owned by institutional investors. 7.2% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 4.9% of Janone shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is DMAC or ALTS more profitable? DiaMedica Therapeutics' return on equity of -43.67% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets DiaMedica TherapeuticsN/A -43.67% -40.81% Janone N/A -2,940.01%-39.81% Do analysts prefer DMAC or ALTS? DiaMedica Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 93.24%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe DiaMedica Therapeutics is more favorable than Janone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Janone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in DMAC or ALTS? DiaMedica Therapeutics received 94 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformDiaMedica TherapeuticsOutperform Votes9463.09% Underperform Votes5536.91% JanoneN/AN/A Does the media refer more to DMAC or ALTS? In the previous week, DiaMedica Therapeutics had 4 more articles in the media than Janone. MarketBeat recorded 6 mentions for DiaMedica Therapeutics and 2 mentions for Janone. Janone's average media sentiment score of 0.96 beat DiaMedica Therapeutics' score of 0.59 indicating that Janone is being referred to more favorably in the news media. Company Overall Sentiment DiaMedica Therapeutics Positive Janone Positive Which has better valuation and earnings, DMAC or ALTS? Janone has higher revenue and earnings than DiaMedica Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDiaMedica TherapeuticsN/AN/A-$19.38M-$0.60-6.90Janone$7.11M8.77-$7.81MN/AN/A SummaryDiaMedica Therapeutics beats Janone on 8 of the 13 factors compared between the two stocks. Remove Ads Get Janone News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricJanonePharmaceutical IndustryFinance SectorNASDAQ ExchangeMarket Cap$62.33M$6.91B$11.42B$8.06BDividend YieldN/A2.73%5.57%4.02%P/E RatioN/A7.2022.8519.03Price / Sales8.77226.0025.7593.17Price / CashN/A65.6717.6134.64Price / Book-6.616.472.774.33Net Income-$7.81M$141.90M$1.04B$247.06M7 Day Performance-6.14%-3.05%0.76%-0.53%1 Month Performance-24.53%-4.63%496.42%-3.74%1 Year PerformanceN/A-8.61%536.70%1.72% Janone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSJanoneN/A$4.43-2.9%N/AN/A$62.33M$7.11M0.00170Short Interest ↓News CoverageDMACDiaMedica Therapeutics1.6723 of 5 stars$5.70-4.8%$7.00+22.8%+50.0%$243.74MN/A-10.1820CDTXCidara Therapeutics4.3998 of 5 stars$22.22-0.2%$39.14+76.2%+40.7%$243.32M$1.28M-0.8790Short Interest ↑OLMAOlema Pharmaceuticals2.761 of 5 stars$4.21-5.4%$28.75+583.1%-62.2%$241.23MN/A-1.9270ACBAurora Cannabis0.4129 of 5 stars$4.39-0.1%N/A+4.8%$240.55M$320.81M87.721,073Gap UpLFCRLifecore Biomedical1.5658 of 5 stars$6.49-0.9%$8.00+23.3%+27.9%$239.74M$130.86M-11.56690ATAIAtai Life Sciences3.3331 of 5 stars$1.39-5.1%$9.00+549.8%-15.0%$232.41M$331,000.00-1.7180Analyst RevisionGap UpKRROKorro Bio1.5118 of 5 stars$24.43-2.5%$144.00+489.6%-79.6%$228.81MN/A0.0070Analyst RevisionGap UpPRMEPrime Medicine2.8637 of 5 stars$1.74-0.9%$13.13+656.5%-70.7%$227.56M$2.98M-0.85234ACIUAC Immune2.8707 of 5 stars$2.23+0.7%$12.00+439.1%-29.9%$226.53M$27.31M-4.90140Short Interest ↑Positive NewsBTMDbiote3.5831 of 5 stars$4.16+4.1%$8.00+92.1%-36.9%$225.50M$197.19M15.96194Positive NewsGap Up Remove Ads Related Companies and Tools Related Companies DMAC Alternatives CDTX Alternatives OLMA Alternatives ACB Alternatives LFCR Alternatives ATAI Alternatives KRRO Alternatives PRME Alternatives ACIU Alternatives BTMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALTS) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janone Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALTS Stock Free ALTS Stock Alerts